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akao Hasegawa, MD,* Ichizo Tsujino, MD, PHD,* Ryota Sakurai, MD, PHD,*
aul G. Yock, MD,* Yasuhiro Honda, MD,* David E. Kandzari, MD,† Martin B. Leon, MD,‡
eter J. Fitzgerald, MD, PHD,* for the ENDEAVOR IV Trial Investigators
tanford and La Jolla, California; and New York, New York
bjectives The aim of this study was to compare the vessel response between zotarolimus-eluting
tents (ZES) and paclitaxel-eluting stents (PES) using intravascular ultrasound.
ackground The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents
n Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting,
hosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared
ith using PES for the same treatment.
ethods Data were obtained from patients with serial (baseline and 8-months follow-up) intravascular
ltrasound analysis available (n  198). Volumetric analysis was performed for vessel, lumen, plaque,
tent, and neointima. Cross-sectional narrowing (given as percentage) was deﬁned as neointimal area
ivided by stent area. Neointima-free frame ratio was calculated as the number of frames without intra-
ascular ultrasound-detectable neointima divided by the total number of frames within the stent. Sub-
egment analysis was performed at every matched 1-mm subsegment throughout the stent.
esults At follow-up, the ZES group showed signiﬁcantly greater percentage of neointimal obstruction
16.6  12.0% vs. 9.9  8.9%, p  0.01) and maximum cross-sectional narrowing (31.8  16.1% vs. 25.2
14.9%, p  0.01) with smaller minimum lumen area than the PES group did. However, the incidence
f maximum cross-sectional narrowing 50% was similar in the 2 groups. Neointima-free frame ratio
as signiﬁcantly lower in the ZES group. In overall analysis, whereas the PES group showed positive re-
odeling during follow-up (13.7  4.2 mm3/mm to 14.3  4.3 mm3/mm), the ZES group showed no
igniﬁcant difference (12.7  3.6 mm3/mm to 12.9  3.5 mm3/mm). In subsegment analysis, signiﬁcant
ocal positive vessel remodeling was observed in 5% of ZES and 25% of PES cases (p  0.05).
onclusions There were different global and focal vessel responses for ZES and PES. Both drug-eluting
tents showed a similar incidence of lesions with severe narrowing despite ZES having a moderate in-
rease in neointimal hyperplasia compared with neointimal hyperplasia in PES. There was a relatively
ower neointima-free frame ratio in ZES, suggesting a greater extent of neointimal coverage. (The EN-
EAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions; NCT00217269)
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780ecently approved by the U.S. Food and Drug Adminis-
ration, the Endeavor zotarolimus-eluting stent (ZES)
Medtronic CardioVascular Inc., Santa Rosa, California) is
drug-eluting stent (DES) that uses the Driver cobalt-
ased alloy platform to deliver 10 g/mm zotarolimus
Abbott Pharmaceuticals, Abbott Park, Illinois) via the
hosphorylcholine polymer (1). The ENDEAVOR IV
Randomized Comparison of Zotarolimus- and Paclitaxel-
luting Stents in Patients With Coronary Artery Disease)
rial was a multicenter study assessing the equivalence of
fficacy and safety between ZES and paclitaxel-eluting stent
PES) for the treatment of de novo coronary artery lesions.
he purpose of this intravascular ultrasound (IVUS) suba-
alysis was to fully describe the vascular responses following
ES implantation compared with those following PES
sing serial IVUS analysis.
ethods
Patients. Data were derived from
the ENDEAVOR IV trial, a mul-
ticenter, single-blind, randomized
2-arm, control study comparing the
efficacy and safety between ZES
and PES for the treatment of de
novo coronary artery lesions. Pa-
tients were stratified by center and
diabetic status and randomized to
either ZES or PES in a 1:1 manner.
The study protocol was approved by
the institutional review board at
each participating site, and consec-
utive, eligible patients signed writ-
ten informed consent prior to the
interventional procedure.
VUS procedure and analysis. The IVUS interrogation was
lanned for all patients at pre-specified enrollment sites
ollowing the procedure and at 8 months after stent implan-
ation. The IVUS procedure was performed in a standard
ashion using automated motorized pullback (0.5 mm/s)
ith commercially available imaging systems (40-MHz
VUS catheter [Boston Scientific Corp., Natick, Massachu-
etts] or 20-MHz IVUS catheter [Volcano Corp., Rancho
ordova, California]). The IVUS analysis was performed at
n independent core laboratory at Stanford University
Cardiovascular Core Analysis Laboratory, Stanford, Cali-
ornia) by clinicians blinded to the treatment arm.
Volumetric measurements were performed using echo-
laque software (Indec Systems Inc., Santa Clara, Califor-
ia) as previously described (2). Neointimal volume was
alculated as stent volume minus lumen volume, and per-
entage of neointimal obstruction was defined as neointimal
olume divided by stent volume. Each volume was divided
bbreviations
nd Acronyms
SN  cross-sectional
arrowing
ES  drug-eluting stent(s)
SA  incomplete stent
pposition
VUS  intravascular
ltrasound
ES  paclitaxel-eluting
tent(s)
I  volume index
ES  zotarolimus-eluting
tent(s)y measurement stent length to adjust for different stent ength (volume index [VI]). Cross-sectional narrowing
[CSN] given as a percentage) was defined as neointima
rea divided by stent area and the cases with maximum CSN
50% were considered as having severe narrowing (3).
eointima-free frame ratio (given as a percentage) was
alculated as the number of frames without IVUS-
etectable neointima divided by the total number of frames
ithin the stent. Peristent plaque volume was calculated as
essel volume minus stent volume. Focal vessel area changes
ere analyzed at every matched 1-mm subsegment through-
ut the stent. Significant focal positive remodeling was
efined as 20% vessel area increase during follow-up in at
east 3 consecutive subsegments.
Tissue prolapse, stent edge dissection, and incomplete
tent apposition (ISA) were assessed by qualitative IVUS
nalysis. We identified ISA as 1 or more struts clearly
eparated from the vessel wall with evidence of blood
peckles behind the strut. Then, ISA was classified as
persistent,” “resolved,” or “late acquired” (4). All images
ere reviewed by 2 independent observers and adjudication
f opinion was based on the consensus of these observers.
tatistical analysis. Statistical analysis was performed using
tatview 5.0 (SAS Institute, Cary, North Carolina). Con-
inuous variables are expressed as mean  SD or median
interquartile range). For continuous variables with normal
istributions, comparisons between ZES and PES were
erformed with a 2-tailed, unpaired t test, and comparisons
etween baseline and follow-up were done by 2-tailed,
aired t test. The Mann-Whitney U statistic test was used
hen normality tests of these variables failed. Categorical
ariables were compared using chi-square test. Correlations
etween vessel volume change and neointimal volume were
nalyzed using the Spearman correlation analysis. A p value
0.05 was considered statistically significant.
esults
tudy population and patient characteristics. Data were
erived from the ENDEAVOR IV clinical trial in which
erial (baseline and 8-months follow-up) IVUS analysis was
ossible in 198 cases (ZES: 100, PES: 98). After excluding
ases with inconsistent pullback, follow-up volumetric anal-
sis was available in 165 cases (ZES: 79, PES: 86), and
erial volumetric analysis was available in 105 cases (ZES:
3, PES: 52). Patient and lesion characteristics are summa-
ized in Table 1. There was no significant difference
etween the entire ENDEAVOR IV trial group and the
VUS subgroup, except for lesion location. Patient and
esion characteristics among the IVUS subgroup were sim-
lar between the ZES and PES groups.
uantitative IVUS analysis. The ZES group demonstrated a
ignificantly greater magnitude of percentage of neointimal
bstruction than the PES group did (16.6  12.0% vs. 9.98.9%, p  0.01) (Table 2, Fig. 1). Maximum CSN was
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781ignificantly higher in the ZES group (31.8  16.1% vs.
5.2  14.9%, p  0.01); however, the incidence of stents
ith severe narrowing (maximum CSN more than 50%) was
imilar between the 2 groups (ZES: 16.5%, PES: 10.5%,
 NS). The ZES group showed significantly lower
eointima-free frame ratio than the PES group did (11.8 
7.4% vs. 30.9  28.2%, p  0.01).
Serial IVUS measurements at in-stent segments are
ummarized in Table 3. In the overall analyses, baseline
VUS measurements within the stent were not significantly
ifferent between the ZES and PES groups except for
inimum lumen area. Although there was a significant
ncrease in vessel volume of the PES group with significant
ncrease in peristent plaque, there was no significant differ-
nce in the ZES group. Delta vessel VI was significantly
ower in the ZES group than in the PES group (delta vessel
I: 0.3  1.0 mm3/mm vs. 0.8  1.0 mm3/mm, p  0.05;
elta peristent plaque VI: 0.2  0.8 mm3/mm vs. 0.7  0.8
m3/mm, p  0.05). In subsegment analyses, delta vessel
rea changes were significantly lower in the ZES group than
n the PES group (1.6  0.8 mm2 vs. 2.2  1.4 mm2, p 
.05) at maximum remodeling site, although there was a
ignificant increase in vessel area during the follow-up
eriod in both stent groups. Per patient analysis, the
ncidence of significant focal positive vessel remodeling
20% vessel area increase) was significantly lower in the
ES group than in the PES group (5% vs. 25%, p  0.05).
Table 1. Baseline Patient and Lesion Characteristics
ZES (n  10
Age, yrs 62.2  11.
Male sex, % 65.0
Hypertension, % 82.0
Hyperlipidemia, % 84.0
Diabetes mellitus, % 32.0
History of smoking, % 59.2
Unstable angina, % 53.6
Target vessel, %, LAD/LCX/RCA 53/21/26
Lesion type (B2/C), % 72.0
Reference vessel diameter by QCA, mm 2.7  0.5
Lesion length by QCA, mm 14.2  5.9
LAD left anterior descending coronary artery; LCX left circumflex coronary artery; NS not sign
artery; ZES zotarolimus-eluting stent(s).
Table 2. Neointimal Characteristics
ZES (n  7
Neointima obstruction, % 16.6  12.0
Median (IQR) 13.8 (7.0–22.
Maximum CSN, % 31.8  16.1
Stent with maximum CSN 50%, n (%) 13 (16.5%)
Neointima-free frame ratio, % 11.8  17.4CSN cross-sectional narrowing; IQR interquartile ranges; other abbreviations as in Table 1.hange in peristent dimensions did not correlate with
eointimal volume in either stent type (ZES: r  0.03, p 
.85; PES: r  0.004, p  0.98).
Regarding reference segments, baseline IVUS mea-
urements were not significantly different between the
ES and PES groups. In proximal reference segments,
here was a significant decrease in lumen volume of PES
ith negative remodeling during the follow-up period.
egarding distal reference segments, ZES lumen volume
howed a significant decrease with an increase in plaque
olume. Delta volume changes (VI at follow-up minus VI
t baseline) were not significantly different between the 2
tent groups (Table 4).
ualitative IVUS analysis. Table 5 summarizes the results of
he qualitative analysis. The incidence of tissue prolapse was
ignificantly higher in the PES group than in the ZES
roup. Late ISA was observed in both the ZES (1 case) and
ES (3 cases) groups; however, there was no significant
ifference between the 2 stent groups.
iscussion
he main findings of this IVUS analysis are as follows: 1)
atients treated with ZES had a greater amount of neoin-
ima than did those treated with PES; 2) the ZES group
howed lower neointima-free frame ratio than did the PES
roup; 3) the ZES group had no significant change in
PES (n  98) p Value
62.8  11.2 NS
62.2 NS
74.5 NS
74.5 NS
30.6 NS
57.1 NS
62.3 NS
51/20/29 NS
65.3 NS
2.7  0.4 NS
14.1  7.0 NS
PES paclitaxel-eluting stent(s); QCA quantitative coronary angiography; RCA right coronary
PES (n  86) p Value
9.9  8.9 0.01
7.7 (2.7–13.0)
25.2  14.9 0.01
9 (10.5%) NS
30.9  28.2 0.010)
7
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782eristent vessel structure, whereas the PES group showed
ositive vessel remodeling during follow-up in the overall
nalysis; 4) the ZES group, when compared with the PES
roup, showed a low incidence of focal vessel remodeling;
nd 5) incidence of late ISA was not significantly different
etween the 2 stent groups.
eointimal hyperplasia formation. The percentage of neo-
ntimal obstruction may represent the overall magnitude of
eointimal suppression of a DES (5). Previous reports have
emonstrated that the percentage of neointimal obstruction
as 29% to 33% in bare-metal stents (6,7), 8% to 13% in
olymer-based PES (8,9), and 16% to 17% in ZES (5,7).
he percentage of neointimal obstruction from our analysis,
Figure 1. Statistical Distribution of Percentage of Neointimal Obstruction
for ZES and PES
The distribution of percentage of neointimal obstruction of zotarolimus-
eluting stent (ZES) was shifted to the right and average percentage of neo-
intimal obstruction was signiﬁcantly higher when compared with
obstruction of paclitaxel-eluting stent (PES) (p  0.01).
Table 3. In-Stent Segment Quantitative IVUS Analysis
ZES (
Entire Stent Segment Analysis Baseline Fo
Vessel VI 12.7 3.6 12
Delta vessel VI 0
Lumen VI 6.6 1.8 5
Delta lumen VI –0
Peristent plaque VI 6.1 2.3 6
Delta peristent plaque VI 0
Minimum lumen area, mm2 5.5 1.5† 4
Late area loss, mm2 1
Subsegment Analysis
Focal vessel remodeling, %
% vessel VI change at maximum remodeling site 13
% plaque VI change at maximum remodeling site 28
*p 0.05 for ZES follow-up vs. PES follow-up, †p 0.05 for ZES baseline vs. PES baseline, ‡p valueIVUS intravascular ultrasound; VI volume index (mm3/mm); other abbreviations as in Table 1..9% in PES and 16.6% in ZES, was consistent with that of
reviously published data describing the same stent
echnology.
In addition to the overall suppression of neointimal
olume, focal accumulation of neointima is another impor-
ant factor that should be incorporated into the analysis.
he IVUS parameters describing focal neointimal charac-
eristics, such as stents with severe narrowing, and late area
oss may be important as well as overall neointimal volume.
e have previously reported that patients treated with ZES
howed more evenly distributed neointimal formation than
hose treated with sirolimus-eluting stents did (5). In this
VUS analysis, the ZES group showed significantly greater
eointimal hyperplasia than the PES group did. However,
tents with severe narrowing and late area loss, both of
hich are relevant to focal neointimal characteristics, were
ot statistically different between the 2 groups. These results
uggest a greater extent of neointimal coverage is present
hroughout the ZES group than in the PES group. There-
ore, the relatively greater neointimal coverage seen in the
ES group may have contributed to minimizing adverse
linical outcomes, despite the greater amount of neointimal
yperplasia seen in the ZES group.
eointimal coverage. Neointimal coverage over stent struts
as been reported using IVUS data. An IVUS analysis from
he TAXUS trial showed that 48.8% of total stent length
as neointima-free in the PES arm and 13.4% of stent
ength was neointima-free in the bare-metal stent arm (10).
n this IVUS subanalysis, the neointima-free frame ratio
as 11.8% and 30.9% for ZES and PES, respectively. In
his study, the neointimal-free frame ratio of the ZES group
as similar to that of the bare-metal stent arm in TAXUS
V and confirming a significantly higher value for the PES
3) PES (n  52)
p p Value Baseline Follow-Up p Value
5 NS 13.6 4.1 14.3 4.3 0.01
0 0.8 1.0*
7 0.01 7.2 2.0 6.6 2.0* 0.01
9 –0.6 0.9
1 NS 6.4 2.6 7.1 2.7 0.01
8 0.7 0.8*
6 0.01 6.2 1.9 5.3 1.9* 0.01
0 0.9 1.1
p Value‡
25.0 0.05
18.2 9.2 0.05
.3 47.2 29.8 0.01
vs. PES.n  5
llow-U
.9 3.
.3 1.
.6 1.
.9 0.
.2 2.
.2 0.
.4 1.
.1 1.
5.0
.7 6.8
.3 20
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783roup. Previous studies have shown that impaired or delayed
eointimal coverage may be associated with stent thrombo-
is (11,12). Although direct assessment of endothelializa-
ion by IVUS is difficult due to limited IVUS resolution,
eointimal coverage based on IVUS may serve as a surrogate
or assessment of the degree of endothelialization.
It is still an open question whether there is an association
etween neointima-free frame ratio and clinical outcomes.
t could theoretically minimize the risk of stent thrombosis
f DES allowed an adequate amount of endothelialization or
eointimal coverage without significantly compromising the
umen (13). Strut coverage throughout the stent may be
rotective and possibly lessen obligatory dependence on
trict long-term antiplatelet therapy. The ideal neointimal
overage for efficacy and safety, however, is yet to be
etermined.
Table 4. Reference Segment Quantitative IVUS Analysis
ZES
Baseline Follow-Up
Proximal
Vessel VI 13.5 4.0 13.4 4.1
Delta vessel VI –0.1 1.4
Lumen VI 7.5 2.8 7.1 2.7
Delta lumen VI –0.4 1.0
Plaque VI 6.3 2.4 6.5 2.4
Delta plaque VI 0.2 1.0
Distal
Vessel VI 10.0 3.5 9.8 3.4
Delta vessel VI –0.2 1.2
Lumen VI 6.1 2.0 5.7 1.8
Delta lumen VI –0.5 1.1
Plaque VI 3.8 2.0 4.0 2.1
Delta plaque VI 0.2 0.6
p NS for ZES baseline vs. PES baseline.
Abbreviations as in Tables 1 and 3.
Table 5. Qualitative IVUS Analysis
ZES (n  100) PES (n  98) p Value
Tissue prolapse, n 10 25 0.01
Stent edge dissection, n
Proximal edge/distal edge 0/0 1/0 NS
ISA
ISA at baseline, n 12 14 NS
Resolved ISA 8 7 NS
Persistent ISA 4 7 NS
Late ISA, n 1 3 NSwISA incomplete stent apposition; other abbreviations as in Table 1.essel remodeling. Previous trials evaluating PES (8,14)
howed significantly increased vessel and plaque volume
uring the follow-up period, whereas those evaluating ZES
5,7) did not show significant changes in vessel volume in
he stented segment. Our IVUS analysis supports these
revious results regarding the peristent vascular response. In
ddition to the global vessel volume change, we performed
etailed IVUS analysis on focal vessel remodeling. Even
hough the ZES group showed no significant change in
essel and plaque volume for the entire stented segment,
ubsegment analysis demonstrated that focal vessel remod-
ling (patient with 20% vessel area increase) was observed
n 5% of ZES cases. Compared with the PES group,
owever, the magnitude and incidence of focal vessel
emodeling were significantly lower in the ZES group.
A previous pathologic report examined the vessel re-
ponse to different DES. In a rabbit experimental model,
he extent of inflammation and fibrin deposit was signifi-
antly higher with PES than with ZES. In addition,
are-metal stents did not show any inflammation and fibrin
eposit after stent implantation (15). Although the mech-
nism underlying positive vessel remodeling after DES is
oorly understood, inflammation is thought to be involved
n this process (16,17). The impact of vessel remodeling on
linical outcome is still unclear, however, careful follow-up
ay be required to elucidate the consequence of these IVUS
ndings.
ate ISA. The occurrence of late ISA have been reported in
% to 13% of sirolimus-eluting stents (4,18,19), 2% to 16%
f PES (18,20,21), and 0% to 1% of ZES (5,7). In this
VUS analysis, late ISA was observed in 1 ZES case, which
PES
alue Baseline Follow-Up p Value
NS 14.4 4.5 14.1 4.3 0.05
–0.3 1.0
0.05 7.7 2.6 7.2 2.7 0.05
–0.5 1.2
NS 6.5 2.9 6.7 2.4 NS
0.2 1.5
NS 11.0 4.2 10.9 4.2 NS
0.0 1.4
0.01 6.6 2.4 6.2 2.3 NS
–0.3 1.5
0.05 4.2 2.7 4.7 2.8 0.05
0.4 1.1p V


as only the second case of late ISA throughout the entire
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784NDEAVOR trial series (ENDEAVOR I, II, III, IV, and
I Continued Access). The incidence of late ISA in this
tudy showed no significant difference between the 2 stents.
tudy limitations. First, this analysis is based on a cohort of
atients who completed serial IVUS examinations, and the
imited sample size may pose a risk for selection bias.
econd, follow-up IVUS analysis was limited to a mid-term
eriod of 8 months. Further studies with longer-term
ollow-up may be necessary to more adequately assess
fficacy and safety. Third, due to limited IVUS resolution
80 m axially and 200 m laterally), the degree of
ndothelialization on stent surface(s) may not be fully
isualized. Fourth, clinical implications of new IVUS pa-
ameters, such as neointima-free frame ratio and focal vessel
esponse, are still an open question. Further investigations
ay be required to clarify the significance of these IVUS
esults.
onclusions
he IVUS analysis from the ENDEAVOR IV trial dem-
nstrated that the ZES and PES groups had different global
nd focal peristent and in-stent vessel responses. Both DES
roups showed a similar incidence of lesions with severe
arrowing, despite the ZES group having a moderate
ncrease in neointimal hyperplasia as compared with neoin-
imal hyperplasia in the PES group. There was a relatively
ower neointima-free frame ratio in the ZES group, sug-
esting a greater extent of neointimal coverage.
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